Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
transcription factor 7 like 2 | 0.485 | 0.846 | 1.00 |
|
disease | 0.700 | None | 0.965 | 37 | 7 | 2006 | 2020 | ||||||||
|
CDK5 regulatory subunit associated protein 1 like 1 | 0.617 | 0.615 | 1.6E-02 |
|
disease | 0.700 | None | 0.984 | 28 | 13 | 2007 | 2019 | ||||||||
|
solute carrier family 30 member 8 | 0.623 | 0.731 | 7.4E-12 |
|
disease | 0.500 | None | 0.963 | 23 | 5 | 2007 | 2019 | ||||||||
|
insulin like growth factor 2 mRNA binding protein 2 | 0.588 | 0.615 | 0.24 |
|
disease | 0.500 | None | 0.972 | 22 | 11 | 2007 | 2019 | ||||||||
|
potassium voltage-gated channel subfamily Q member 1 | 0.485 | 0.769 | 4.5E-08 |
|
disease | 0.500 | None | 0.972 | 21 | 16 | 2008 | 2019 | ||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.200 | None | 1.000 | 19 | 38 | 2005 | 2019 | |||||||||
|
translocase of outer mitochondrial membrane 40 | 0.590 | 0.538 | 0.99 |
|
disease | 0.500 | None | 0.978 | 19 | 20 | 2009 | 2020 | ||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.140 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
POU class 5 homeobox 1B | 0.670 | 0.346 | 2.9E-04 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | ||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.140 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 | |||||||||
|
cancer susceptibility 8 | 0.670 | 0.462 |
|
disease | 0.100 | None | 1.000 | 18 | 5 | 2007 | 2019 |